Cyclosporine a Directly Affects Human and Mouse B Cell Migration in Vitro by Disrupting a HIF-1 αdependent, O Sensing, Molecular Switch
Overview
Authors
Affiliations
Background: Hypoxia is a potent molecular signal for cellular metabolism, mitochondrial function, and migration. Conditions of low oxygen tension trigger regulatory cascades mediated via the highly conserved HIF-1 α post-translational modification system. In the adaptive immune response, B cells (Bc) are activated and differentiate under hypoxic conditions within lymph node germinal centers, and subsequently migrate to other compartments. During migration, they traverse through changing oxygen levels, ranging from 1-5% in the lymph node to 5-13% in the peripheral blood. Interestingly, the calcineurin inhibitor cyclosporine A is known to stimulate prolyl hydroxylase activity, resulting in HIF-1 α destabilization and may alter Bc responses directly. Over 60% of patients taking calcineurin immunosuppressant medications have hypo-gammaglobulinemia and poor vaccine responses, putting them at high risk of infection with significantly increased morbidity and mortality.
Results: We demonstrate that O tension is a previously unrecognized Bc regulatory switch, altering CXCR4 and CXCR5 chemokine receptor signaling in activated Bc through HIF-1 α expression, and controlling critical aspects of Bc migration. Our data demonstrate that calcineurin inhibition hinders this O regulatory switch in primary human Bc.
Conclusion: This previously unrecognized effect of calcineurin inhibition directly on human Bc has significant and direct clinical implications.
Hypoxia and the Hypoxia-Inducible Factors in Lymphocyte Differentiation and Function.
Boothby M, Cho S Adv Exp Med Biol. 2024; 1459:115-141.
PMID: 39017842 DOI: 10.1007/978-3-031-62731-6_6.
Ruan H, Zhang Q, Zhang Y, Li S, Ran X Crit Care. 2024; 28(1):100.
PMID: 38539163 PMC: 10976824. DOI: 10.1186/s13054-024-04885-4.
Kassis G, Palshikar M, Hilchey S, Zand M, Thakar J J Theor Biol. 2024; 583:111769.
PMID: 38423206 PMC: 11046450. DOI: 10.1016/j.jtbi.2024.111769.
Jovanovic M, Sabovic M J Med Case Rep. 2023; 17(1):470.
PMID: 37885023 PMC: 10605860. DOI: 10.1186/s13256-023-04174-8.
B Cell Tolerance and Targeted Therapies in SLE.
Parodis I, Long X, Karlsson M, Huang X J Clin Med. 2023; 12(19).
PMID: 37834911 PMC: 10573616. DOI: 10.3390/jcm12196268.